Streetbeat News

Analyst Ratings

TSX:ENB

National Bank Financial Inc's analyst Patrick Kenny has reinstated Enbridge (TSX:ENB) with a Sector Perform rating and announced a price target of C$53.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2023 | 1:22 pm

ESTE

Capital One analyst Brian Velie has downgraded Earthstone Energy (NYSE:ESTE) from Overweight to Equal-Weight and set a price target of $20.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2023 | 1:20 pm

SGHT

B of A Securities analyst Bob Hopkins has downgraded Sight Sciences (NASDAQ:SGHT) from Neutral to Underperform and lowered the price target from $10 to $4.5.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2023 | 1:19 pm

ORCL

Monness, Crespi, Hardt analyst Brian White has downgraded Oracle (NYSE:ORCL) from Buy to Neutral.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2023 | 1:18 pm

DOOO

Citigroup analyst James Hardiman has upgraded BRP (NASDAQ:DOOO) from Neutral to Buy and set a price target of $94.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2023 | 1:16 pm

CCJ

GLJ Research analyst Gordon Johnson has maintained a 'Buy' rating on Cameco (NYSE:CCJ) and raised the price target from C$52 to C$66.45.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2023 | 1:13 pm

FXI

LULU

Lululemon Athletica's CFO stated at the Goldman Sachs Conference that the company is still in the early stages of its growth trajectory in China, which could help it weather any near-term headwinds.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2023 | 1:12 pm

BCYC

Cantor Fitzgerald analyst Li Watsek has reiterated an Overweight rating on Bicycle Therapeutics (NASDAQ:BCYC) and maintained a $65 price target.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2023 | 1:04 pm

MLTX

Cantor Fitzgerald analyst Prakhar Agrawal has reiterated an Overweight rating on MoonLake (NASDAQ:MLTX) and maintained a $65 price target.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2023 | 1:03 pm

RCUS

Cantor Fitzgerald analyst Alethia Young has reiterated an Overweight rating on Arcus Biosciences (NYSE:RCUS) and maintained a $46 price target.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2023 | 1:02 pm